Pacira BioSciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell PCRX and other ETFs, options, and stocks.

About PCRX

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. 

CEO
Frank D. Lee
CEOFrank D. Lee
Employees
790
Employees790
Headquarters
Tampa, Florida
HeadquartersTampa, Florida
Founded
2006
Founded2006
Employees
790
Employees790

PCRX Key Statistics

Market cap
1.14B
Market cap1.14B
Price-Earnings ratio
59.43
Price-Earnings ratio59.43
Dividend yield
Dividend yield
Average volume
981.99K
Average volume981.99K
High today
$26.63
High today$26.63
Low today
$26.01
Low today$26.01
Open price
$26.04
Open price$26.04
Volume
424.24K
Volume424.24K
52 Week high
$27.64
52 Week high$27.64
52 Week low
$18.17
52 Week low$18.17

Stock Snapshot

With a market cap of 1.14B, Pacira BioSciences(PCRX) trades at $26.51. The stock has a price-to-earnings ratio of 59.43.

On 2025-12-29, Pacira BioSciences(PCRX) stock moved within a range of $26.01 to $26.63. With shares now at $26.51, the stock is trading +1.9% above its intraday low and -0.5% below the session's peak.

Trading volume for Pacira BioSciences(PCRX) stock has reached 424.24K, versus its average volume of 981.99K.

Over the past 52 weeks, Pacira BioSciences(PCRX) stock has traded between a high of $27.64 and a low of $18.17.

Over the past 52 weeks, Pacira BioSciences(PCRX) stock has traded between a high of $27.64 and a low of $18.17.

PCRX News

Simply Wall St 6d
How Investors May Respond To Pacira BioSciences Joining AI-Driven PROBE Osteoarthritis Consortium

In December 2025, Pacira BioSciences announced it had joined the European Innovative Health Initiative-funded PROBE Consortium, a global public-private effort u...

How Investors May Respond To Pacira BioSciences Joining AI-Driven PROBE Osteoarthritis Consortium
TipRanks 7d
Pacira Ends Hip Osteoarthritis Injection Study for ZILRETTA: What Investors Should Know

Pacira (PCRX) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and...

Analyst ratings

57%

of 7 ratings
Buy
57.1%
Hold
28.6%
Sell
14.3%

People also own

Based on the portfolios of people who own PCRX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.